Last updated: February 16, 2026
What is NDC 43598-0426?
NDC 43598-0426 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy approved by the FDA in May 2019. It is used for treating spinal muscular atrophy (SMA) in pediatric patients under two years old. Zolgensma is administered as a one-time intravenous infusion.
Market Size and Patient Population
Disease Overview
- Spinal Muscular Atrophy (SMA): A rare genetic disorder characterized by progressive muscle weakness, with an incidence estimated at 1 in 10,000 live births.
- The U.S. birth rate approximates 4.1 million annually, with about 400 new SMA cases each year.
Patient Population
- SMA Type 1 is the most severe form and typically diagnosed within the first 6 months.
- Estimated eligible U.S. population: ~300-400 infants annually for Zolgensma, considering diagnosis rates and age restrictions.
Current Market Penetration and Adoption
- Zolgensma has captured a significant share of the infant SMA treatment market.
- As of 2022, approximately 300-350 doses delivered in the U.S. annually [1].
- Other treatments, such as Spinraza (nusinersen) and Evrysdi (risdiplam), target broader age groups but are administered repeatedly, contrasting with Zolgensma’s one-time dosing.
Pricing and Reimbursement Landscape
List Price
- Wholesale acquisition cost (WAC): $2.125 million per dose [2].
- The high upfront cost prompted multiple payor negotiations, value-based agreements, and risk-sharing reimbursement models.
Insurance and Payer Dynamics
- Coverage has improved due to its transformative potential.
- Insurance companies often restrict access through prior authorizations.
- Manufacturer offers risk-sharing programs, offering rebates if the treatment does not achieve specified outcomes.
Market Trends and Competitive Position
- The gene therapy is positioned as the first one-time treatment for SMA.
- Adoption growth depends on early diagnosis, newborn screening initiatives, and payer acceptance.
- Accelerated approval pathways and orphan drug designation aid market expansion.
Price Projections and Future Trends
| Year |
Estimated Pricing Outlook |
Key Factors influencing prices |
| 2023 |
Slight decline to $2 million-$2.1 million |
Payer negotiations, rebate agreements, increased competition from emerging gene therapies |
| 2024 |
Stabilization or modest decrease to $1.9 million-$2.0 million |
Expanded insurer coverage, increased use in broader patient populations |
| 2025 |
Potential decrease to $1.8 million-$1.9 million |
Entry of biosimilar/pipeline competitors, improved manufacturing efficiencies |
Factors Impacting Price Trends
- Market Expansion: As newborn screening widens, the number of treated patients increases, potentially lowering per-unit costs.
- Manufacturing Advances: Streamlining gene therapy production may reduce costs, enabling price reductions.
- Reimbursement Models: Risk-sharing reimbursements and outcomes-based agreements influence effective pricing.
- Competitive Entries: Future gene therapies or biosimilars could decrease market prices.
Regulatory and Market Entry Barriers
- Regulatory Approvals: Additional indications could expand the market.
- Manufacturing Complexity: Producing gene therapies is logistically challenging and expensive, supporting high pricing.
- Market Penetration: Limited by diagnosis timing, healthcare infrastructure, and payer policies.
Key Takeaways
- NDC 43598-0426 (Zolgensma) commands a high list price, approximately $2.125 million per dose.
- The total market is constrained by a small patient population, with roughly 300-400 infants treated annually in the U.S.
- Reimbursement is variable, often contingent on outcome-based agreements.
- Market growth depends on early diagnosis, expanding indications, and payer acceptance.
- Price projections suggest marginal declines over the next two years driven by manufacturing, reimbursement models, and competitive dynamics.
FAQs
1. How does Zolgensma compare with other SMA treatments?
Zolgensma offers a one-time infusional therapy with higher upfront costs but potentially better long-term outcomes compared to recurrent treatments like Spinraza or Evrysdi, which require multiple doses over time.
2. Will Zolgensma’s price decrease significantly in the near term?
Prices are expected to slightly decline due to improved manufacturing efficiencies, expanded coverage, and negotiations but are unlikely to drop below $1.8 million per dose within the next two years.
3. How does payer coverage influence market expansion?
High costs prompt insurer restrictions; expanded newborn screening and outcomes-based negotiating improve access and utilization.
4. Are biosimilars or alternative therapies expected to impact Zolgensma’s market share?
Yes, pipeline gene therapies and biosimilars could pressure prices and market share once approved, but regulatory and manufacturing hurdles limit immediate impact.
5. What factors could influence the future valuation of this drug?
Regulatory approvals for broader indications, improved manufacturing, increased diagnosis rates, and competitive offerings are primary factors.
Sources
[1] National Institute of Neurological Disorders and Stroke, 2022 Report.
[2] Novartis official pricing disclosures, 2022.
